Case reports: chemoradiotherapy for locally advanced neuroendocrine carcinoma of the gallbladder

Yuma Takeda1 · Noritoshi Kobayashi1 · Takaomi Kessoku2,3 · Naoki Okubo1 · Akihiro Suzuki1 · Motohiko Tokuhisa1 · Haruo Miwa4 · Naoko Ueda5 · Yasushi Ichikawa1

Received: 28 February 2022 / Accepted: 9 May 2022 / Published online: 2 June 2022 © The Author(s) 2022

Abstract
Neuroendocrine carcinoma (NEC) is a rare subtype of malignant gallbladder tumor. Although surgical resection is the only potentially curative therapy for gallbladder NEC, most cases are surgically unresectable because of advanced stage disease and/or biologically aggressive behavior. The standard palliative treatment for malignant gallbladder tumors is chemotherapy; however, the efficacy of chemoradiotherapy in the treatment of gallbladder tumors is controversial. Here, we report a case of gallbladder NEC that showed a durable response to chemoradiotherapy. A 68-year-old Japanese man presented with a huge gallbladder tumor with liver and duodenal invasion. Pathological findings revealed poorly differentiated NEC of the gallbladder. After seven cycles of chemotherapy comprising cisplatin and irinotecan, computed tomography (CT) revealed remarkable tumor shrinkage, but an enlarged portal lymph node. The patient was treated with 50.4 GY in 28 fractions with two cycles of cisplatin and etoposide. After chemoradiotherapy, the enlarged lymph node also decreased in size. Maximum standardized uptake value of fluorodeoxyglucose-positron emission tomography/CT (FDG-PET/CT) changed from 8.2 to physiological accumulation. We defined this condition as a complete response on both enhanced CT and FDG-PET/CT; therefore, we did not perform systemic treatment and only observed his condition. This patient remained healthy with no recurrence at 3 years after chemoradiotherapy.

Keywords Neuroendocrine tumor · Neuroendocrine carcinoma · Gallbladder · Chemoradiotherapy · Complete response

Introduction

Neuroendocrine neoplasms (NENs) originate from neuroendocrine cells located throughout the whole body, most commonly in the pancreas, lung, and gastrointestinal tract [1, 2].

NENs are generally subclassified by primary lesion and pathological findings, including tumor differentiation and grade. Neuroendocrine carcinoma (NEC) is defined as a poorly differentiated and high-grade tumor. NEC is diagnosed upon pathological examination with immunohistochemical staining according to the 2019 World Health Organization (WHO) classification of tumors of the digestive system [3].

NEC is a rare subtype of gallbladder tumor that accounts for 0.5% of all NENs and 2% of all gallbladder tumors [2]. Almost all patients with NEC of the gallbladder are diagnosed incidentally based on pathological examination, including immunohistochemical findings [4]. The clinicopathological characteristics and standard treatment strategy for NEC of the gallbladder remains undetermined due to its rarity. Further, although surgical resection is the only potentially curative therapy for gallbladder NEC, most cases cannot be surgically resected because of advanced stage disease and/or locally aggressive behavior. The standard palliative treatment for malignant gallbladder tumors is chemotherapy;...
however, the efficacy of chemoradiotherapy in the treatment of gallbladder tumors is controversial. We herein describe a case of gallbladder NEC in which the patient underwent chemoradiotherapy and showed a complete response to chemoradiotherapy.

Case report

A 68-year-old man with no comorbidities presented to a local hospital with worsening back pain for two weeks. Contrast computed tomography (CT) of the abdomen and pelvis showed a huge mass of 130 mm with liver and duodenal invasion (Fig. 1a). There was no evidence of a mass or metastatic disease in the chest, bone, or brain.

Subsequently, the endoscopic duodenal and liver biopsy specimens were indicative of proliferation of small round cells with high nuclear-to-cytoplasmic ratios and a poorly differentiated adenocarcinoma (Fig. 2a). Thereafter, immunohistochemical staining revealed that the tumor cells were diffuse positive for synaptophysin and CD56 and negative for chromogranin A (Fig. 2b, c). The Ki-67 labeling index of the tumor from the liver specimen was 68.1% (Fig. 2d). Based on pathological and imaging findings, a final diagnosis of neuroendocrine carcinoma (small cell type) of gallbladder origin with liver and duodenal invasion was made.
The tumor was deemed unresectable due to its very huge size and because it was locally advanced with invasion of the surrounding organs. Therefore, palliative chemotherapy was administered.

The patient received five cycles of chemotherapy consisting of cisplatin and irinotecan. CT findings revealed shrinkage of the primary gallbladder tumor (Fig. 1b and c). However, slight enlargement of the hepatic hilar lymph node was observed (Fig. 1d). After an additional two cycles of chemotherapy, CT revealed apparent hepatic lymph node swelling (max 28 mm) (Fig. 1e). Fluorodeoxyglucose-positron emission tomography/CT (FDG-PET/CT) revealed high uptake in this lesion (Maximum standardized uptake value, SUV max 8.2) (Fig. 1f, g). This is considered a progressive disease associated with chemotherapy. He was then referred to our hospital for further treatment. The physical examination results were unremarkable. He underwent routine blood tests, which revealed no remarkable changes, including tumor markers (Table 1).

At first, we considered and recommended surgical resection, but the patient refused our proposal. He had already received first-line chemotherapy. However, the evidence for second-line chemotherapy is not established, and it is very important to control local progression in this case. Therefore, we decided to administer chemoradiotherapy comprising cisplatin and etoposide based on multidisciplinary decision-making. Radiotherapy was performed

Table 1 Laboratory findings before chemoradiotherapy

| Serum parameter | Normal range | Before chemoradiotherapy |
|-----------------|--------------|--------------------------|
| WBC (/µL)       | 3.3–8.6      | 4700                     |
| Hb (g/dL)       | 13.7–16.8    | 11.6                     |
| PLT (×10^4/µL)  | 158–348      | 145                      |
| AST (IU/L)      | 13–30        | 22                       |
| ALT (IU/L)      | 10–42        | 18                       |
| T-Bil (mg/dL)   | 0.4–1.5      | 0.5                      |
| Cre (mg/dL)     | 0.65–1.07    | 1.04                     |
| TP (g/dL)       | 6.6–8.1      | 6.9                      |
| Alb (g/dL)      | 4.1–5.1      | 4.1                      |
| CRP (mg/dL)     | <0.14        | 0.04                     |
| CEA (ng/mL)     | 0.6–3.8      | 3.2                      |
| CA19-9 (U/mL)   | 1–29         | 1                        |
| NSE (ng/mL)     | <16.3        | 9.0                      |
| Pro GRP (pg/mL) | <81          | 56.7                     |

WBC white blood cells, Hb hemoglobin, PLT platelet test, AST aspartate aminotransferase, ALT alanine aminotransferase, T-Bil bilirubin test, Cre creatinine, TP total protein, Alb albumin, CRP C-reactive protein, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, NSE neuron specific enolase, pro GRP pro-gastrin-releasing peptide
after chemoradiotherapy. The patient remained healthy with no recurrence for 3 years measured tumor markers and performed CT every 4 months. Therefore, we considered a complete response and closely followed up his condition without systemic treatment; we measured tumor markers and performed CT every 4 months. The patient remained healthy with no recurrence for 3 years after chemoradiotherapy.

**Discussion**

Chemoradiotherapy has not historically played a major role in the treatment of gallbladder NEC. However, this report indicates that chemoradiotherapy could be an effective treatment option to achieve local control in the management of gallbladder NEC.

Primary NENs can occur anywhere in the body, regardless of the presence of enterochromaffin cells; NEN of the gallbladder comprises 0.5% of the overall NEN incidence and constitutes 2% of gallbladder cancers [2]. NEC is distinguished from neuroendocrine tumors (NETs) by pathological findings of poor differentiation and high-grade tumor. The tumor grade is defined by the mitotic count and Ki-67 labeling index. In the current WHO guideline, NEC is considered a high-grade tumor. Previously, grade 1 and 2 tumors were regarded as NETs and grade 3 neoplasms as NECs [5]. In the intervening years, grade 3 NETs were recognized and shown to be genetically unrelated to NECs. The new classification avoids confusion between these two clinically and molecularly distinct entities [1].

The clinical presentations of most patients with gallbladder NEC are nonspecific, and the most common early manifestation is vague upper abdominal pain [6]. NENs can be classified as functional or non-functional based on the production of peptide substances. Non-functional NENs manifest as symptoms of local disease, such as abdominal pain, weight loss, and jaundice, or symptoms due to metastatic disease. Functional NENs can give rise to symptoms related to the secretion of different peptides in addition to symptoms of local or metastatic disease [7].

It is almost impossible to ascertain the diagnosis of NEC based on imaging findings such as ultrasonography, CT, magnetic resonance imaging (MRI), and PET/CT. It is also impossible to differentiate NEC from other subtypes of gallbladder carcinomas preoperatively. Pathologic examination with immunohistochemical staining is required for a definitive diagnosis of gallbladder NEC. The tumor can stain positive for synaptophysin in 75% of NECs, followed by chromogranin A. In cases of functional NEC, urine 5-hydroxyindoleacetic acid and nuclear imaging studies, such as somatostatin scintigraphy or MIBG, may be useful for diagnosing and evaluating the therapeutic response. Microscopically, NECs appeared as atypical round and oval, small- to intermediate-sized cells with minimal cytoplasm growing in the form of sheets, clusters, or ribbons, often with necrosis and prominent angioinvasion and/or perineural invasion with high mitotic (>20/10 HPF) and proliferation (Ki-67 > 20%) indices.

Although surgical resection is the only potentially curative therapy for NEC of the gallbladder, most tumors are not surgically resectable. As with other gallbladder carcinomas, NEC can rapidly invade the adjacent liver parenchyma and later cause obstructive jaundice, hindering detection at an early stage. Due to the aggressive tumor behavior and asymptomatic feature at an early stage, patients are often diagnosed at an advanced stage with unresectable and/or metastatic disease, and accordingly have a poor prognosis [8, 9].

Systemic chemotherapy remains the treatment of choice for cases with inoperable or metastasized tumor and can be considered in cases with tumor involvement of the surgical margins. According to a European clinical guideline, cisplatin/etoposide or carboplatin/etoposide is recommended as the standard first-line systemic chemotherapy [10]. In addition, a Japanese clinical guideline recommended platinum-doublet chemotherapy for unresectable and metastatic gastroenteropancreatic (GEP)-NEC [11]. However, there is no established second-line therapy for GEP-NEC. In addition, the role of radiation in GEP-NEC remains unclear. The combination of cisplatin and gemcitabine is a standard chemotherapy for gallbladder carcinoma. However, the efficacy of this regimen was controversial for this case because of the pathological diagnosis as NEC and platinum treatment failure. The role of radiotherapy in the treatment of locally advanced but non-metastatic gallbladder cancer remains unclear. Radiotherapy may be considered in patients with locally controlled disease after first-line chemotherapy [12]. For small cell lung cancer, chemoradiotherapy is recommended for unresectable local disease to improve overall survival and control local progression [13]. The efficacy of chemoradiotherapy for NEC of the gallbladder remains unknown. Few reports have demonstrated that chemoradiotherapy achieved local control in patients with NEC of the gallbladder and prolonged survival (Table 2). According to the literature, one case of NEC of the gallbladder with liver invasion and adjacent liver metastasis achieved a complete response at 12 months after chemoradiotherapy [14].
In our case, the patient had already received first-line chemotherapy. However, the evidence for second-line chemotherapy has not been established, and it is very important to control local progression, especially in this case. Therefore, we decided to administer chemoradiotherapy consisting of cisplatin and etoposide according to the regimen for small cell lung carcinoma. The dose of etoposide was low because of the long duration of the previous chemotherapy. However, this case is highly valuable, although there are very few studies on the treatment outcome of chemoradiotherapy for NEC of the gallbladder, which is a rare pathological feature and a very aggressive and lethal disease.

In conclusion, our experience demonstrates that chemoradiotherapy can be used as an effective treatment option for the management of unresectable locally advanced NEC of the gallbladder. NEC of the gallbladder has a poorer prognosis because of its decreased responsiveness to chemotherapy. Chemoradiotherapy may induce a tumor response and achieve tumor control in locally advanced gallbladder NEC. The future role of radiation in combination with chemotherapy or biologic modifiers for the treatment of NEC of the gallbladder remains controversial. We suggest that chemoradiotherapy should be considered part of multimodality therapy for the curative management of advanced NEC of the gallbladder.

Acknowledgements We would like to thank Editage (https://editage.jp) for editing the manuscript draft and for providing help in drafting the abstract.

Author contributions YT and NK participated in the study design. YT, NO, TK, AS, MT, NU and YI participated in the interpretation. All authors contributed to writing, reading, and approving the final manuscript.

Funding This study received no funding.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655–64.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.
3. Nagtegaal ID, Odze RD, Klimstra D, et al. WHO classification of tumours editorial board; for the WHO classification of tumours editorial board. Histopathology. 2020;76:182–8.
4. Mezi S, Petrozza V, Schillaci O, et al. Neuroendocrine tumors of the gallbladder: a case report and review of the literature. J Med Case Rep. 2011;5:334.
5. Bosman F, Carneiro F. World Health Organization classification of tumours, pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2010.
6. Kim J, Lee WJ, Lee SH, et al. Clinical features of 20 patients with curatively resected biliary neuroendocrine tumours. Dig Liver Dis. 2011;43:965–70.
7. Pavithran K, Prabhak K, Hazarika D, et al. Neuroendocrine carcinoma of gallbladder: report of 2 cases. Hepatobiliary Pancreat Dis Int. 2005;4:144–6.
8. Eltawil KM, Gustafsson BI, Kidd M, et al. Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy. J Clin Gastroenterol. 2010;44:687–95.
9. Albores-Saavedra J, Batsik K, Hossain S, et al. Carcinoid tumors and small-cell carcinomas of the gallbladder and extrahepatic bile ducts: a comparative study based on 221 cases from the surveillance, epidemiology, and end results program. Ann Diagn Pathol. 2009;13:378–83.
10. Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844–60.
11. Ito T, Masui T, Komoto I, et al. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms:
diagnosis, treatment, and follow-up: a synopsis. J Gastroenterol. 2021;56:1033–44.
12. Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28–37.
13. Kalemkerian GP, Loo BW, Akerley W, et al. NCCN guidelines insights: Small cell lung cancer. Version 2. Natl Compr Canc Netw. 2018;16(10):1171–82.
14. Lee J, Choi J, Choi C, et al. Role of radiotherapy for pancreatobiliary neuroendocrine tumors. Radiat Oncol J. 2013;31:125–30.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.